A Microfluidic Model for Safer Drug Development
A significant advance in predictive toxicology has been reported with the development of a robust microfluidic glomerular filtration barrier-on-a-chip platform. This innovative technology enables the detailed investigation of drug-induced nephrotoxicity by replicating the kidney’s critical filtration unit. The platform allows for real-time, high-resolution analysis of how potential therapeutics affect the glomerular structure and function, providing a more accurate and human-relevant model than traditional cell cultures or animal studies for assessing renal safety in pharmaceutical development.
Study Significance: For gastroenterologists and hepatologists, this technology is methodologically adjacent and highly relevant, as many systemically administered drugs and novel biologics for conditions like inflammatory bowel disease or hepatocellular carcinoma carry potential renal risks. This platform could be adapted to model other specialized barriers, such as the gut-blood barrier, to directly study drug absorption and local toxicity in the gastrointestinal tract. Its implementation could refine early-stage drug screening, leading to safer therapeutic pipelines and more personalized risk assessment for patients with complex digestive and liver diseases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
